Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17343063 | 0.89 | ALDH1A1 (0.51) | KMT2ABRD4NLRP3GAAALDH1A1 | |
| SCHEMBL17343060 | 0.88 | POLB (0.54) | EPHX2KMT2APOLBGAAALDH1A1 | |
| SCHEMBL17343061 | 0.84 | KMT2A (0.57) | EPHX2KMT2APOLBGAAALDH1A1 | |
| SCHEMBL17331321 | 0.78 | ALDH1A1 (0.56) | KMT2APOLBGAAALDH1A1TDP1 | |
| SCHEMBL13504015 | 0.75 | TSHR (0.69) | KMT2APOLBALDH1A1MAPTHTT | |
| SCHEMBL17343062 | 0.74 | ALDH1A1 (0.60) | KMT2APOLBGAAALDH1A1MAPT | |
| SCHEMBL17347543 | 0.73 | FABP4 (0.49) | KMT2APOLBALDH1A1TSHRMAPK1 | |
| SCHEMBL5216545 | 0.72 | HTR1F (0.58) | KMT2ABRD4NLRP3ALDH1A1TSHR | |
| SCHEMBL18311852 | 0.71 | MEN1 (0.59) | EPHX2KMT2APOLBALDH1A1MAPT | |
| SCHEMBL1051520 | 0.71 | ALDH1A1 (0.54) | KMT2APOLBALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701627-B2 | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701627-B2 | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-12-17 | — | — | US | disclosed |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | LRRK2, PARK7, SNCA | EPHX2 3964/4885KMT2A 2480/4885BRD4 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.